Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.68 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | NCF1 | P14598 | 1/20 | 0.61 |
| ▸ | DRD4 | P21917 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | CYP2A13 | Q16696 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.57 |
| ▸ | MC4R | P32245 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL948372 | 1.00 | SIGMAR1 (0.68) | SIGMAR1HRH3ALDH1A1HTTKDM4E | |
| SCHEMBL896379 | 1.00 | SIGMAR1 (0.68) | SIGMAR1HRH3ALDH1A1HTTKDM4E | |
| SCHEMBL102338 | 0.98 | SIGMAR1 (0.71) | SIGMAR1HRH3ALDH1A1HTTKDM4E | |
| SCHEMBL6200777 | 0.98 | SIGMAR1 (0.71) | SIGMAR1HRH3ALDH1A1HTTKDM4E | |
| Water SCHEMBL1702298 | 0.96 | SIGMAR1 (0.68) | SIGMAR1HRH3ALDH1A1HTTKDM4E | |
| Hydrochloric Acid SCHEMBL6261135 | 0.96 | SIGMAR1 (0.68) | SIGMAR1HRH3ALDH1A1HTTKDM4E | |
| SCHEMBL28158277 | 0.96 | SIGMAR1 (0.68) | SIGMAR1HRH3ALDH1A1HTTKDM4E | |
| SCHEMBL6384833 | 0.94 | HRH3 (0.61) | SIGMAR1HRH3ALDH1A1HTTKDM4E | |
| SCHEMBL18309364 | 0.94 | HRH3 (0.61) | SIGMAR1HRH3ALDH1A1HTTKDM4E | |
| SCHEMBL24200050 | 0.93 | HRH3 (0.62) | SIGMAR1HRH3ALDH1A1HTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180201590-A1 | AZOCANE AND AZONANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2018-07-19 | — | — | US | disclosed |
| US-20180201590-A1 | AZOCANE AND AZONANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2018-07-19 | — | — | US | disclosed |
| US-20180201590-A1 | AZOCANE AND AZONANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2018-07-19 | — | — | US | disclosed |
| US-9884831-B2 | Azocane and azonane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884831-B2 | Azocane and azonane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884831-B2 | Azocane and azonane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| EP-3271019-A1 | AZOCANE AND AZONANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | Novira Therapeutics Inc. (US) | 2018-01-24 | — | — | EP | disclosed |
| WO-2016149581-A1 | AZOCANE AND AZONANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. (US) | 2016-09-22 | — | — | WO | disclosed |
| WO-2016149581-A1 | AZOCANE AND AZONANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. (US) | 2016-09-22 | — | — | WO | disclosed |
| US-20160272599-A1 | AZOCANE AND AZONANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2016-09-22 | — | — | US | disclosed |
| US-20160272599-A1 | AZOCANE AND AZONANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2016-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272599-A1 | AZOCANE AND AZONANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HCCS, SLC10A1 | SIGMAR1 4558/4885HRH3 2682/4885ALDH1A1 2044/4885 |
| US-20180201590-A1 | AZOCANE AND AZONANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HCCS, SLC10A1 | SIGMAR1 4558/4885HRH3 2682/4885ALDH1A1 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.